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Objectives. We sought to study the renal circulatory effects of
adenosine in patients with chronic congestive heart failure (CHF).
Background. Renal blood flow (RBF) is often reduced in
patients with chronic CHF and may lead to decreased renal function.
The cause of reduced RBF is multifactorial and involves systemic as
well as local vasoregulatory mechanisms. Stimulation of renal aden-
osine A1 receptors in animal models has resulted in a significant
vasoconstriction of afferent and efferent glomerular arterioles and
deterioration of renal function. Although adenosine serum levels
have been shown to be elevated in patients with CHF, their effect on
the renal circulation in this patient population has not been studied.
Methods. Nine patients with CHF from left ventricular systolic
dysfunction were studied. The effects of adenosine at a dose of
1025 mol/liter infused directly into the main renal artery on heart
rate, renal artery blood pressure, renal artery cross-sectional area
(measured by intravascular ultrasound), renal Doppler blood flow
velocity (measured by a Doppler flow wire in the renal artery),
RBF and renal vascular resistance (RVR) were evaluated.
Results. Infusion of adenosine resulted in no significant effect
on heart rate or renal artery blood pressure but caused a
substantial increase in RVR (11,204 6 1,469 to 31,494 6 3,911
dyneszszcm25, p 5 0.0005), which led to a marked fall in RBF in
every patient (mean values 376 6 36 to 146 6 22 ml/m2, p 5
0.0002). These changes in RVR and RBF were associated with no
significant change in renal artery cross-sectional area (0.389 6
0.040 to 0.375 6 0.033 cm2, p 5 0.3).
Conclusions. Stimulation of renal adenosine receptors in pa-
tients with CHF results in marked renal vasoconstriction that
leads to an important reduction in RBF. Lack of change in renal
artery cross-sectional area suggests that adenosine affects intra-
renal resistance blood vessels rather than large conductance
vessels. These results may indicate a rationale for investigation of
renal adenosine receptor blockade for enhancement of RBF and
improvement of renal function in patients with chronic CHF.
(J Am Coll Cardiol 1998;32:211–5)
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Reduction of renal blood flow (RBF) is common in patients
with congestive heart failure (CHF) and is the principal
determinant of impaired glomerular filtration rate in these
patients (1,2). Although a fall in RBF accompanies a decline in
cardiac output in these patients, intrarenal hemodynamic
variables are also mediated by local vasoregulatory mecha-
nisms (2,3). An understanding of such mechanisms is a pre-
requisite for any attempt to develop therapeutic strategies for
enhancement of RBF and improvement of renal function in
patients with CHF.
Adenosine is an ubiquitous nucleoside that is present in
normal kidneys (4,5). The physiologic effects of endogenous
adenosine are mediated by activation of two major subtypes of
membrane-bound receptors, allowing an important regulation
of renal hemodynamic variables and function (4–8). Although
exposure to adenosine leads to a marked vasodilatory effect in
most vascular beds, the vasoregulatory effect of the drug in the
kidney is more complex and heterogenous (8). Adenosine
administration in various animal models resulted in different
effects (9–11). The drug decreased RBF in salt-depleted rats
(9) but increased RBF in sodium-loaded rats. Similarly, studies
in humans demonstrated inconsistent results (12–14). Al-
though adenosine was reported to dilate the renal vasculature
in healthy subjects (14) and in patients with hypertension (13),
it decreased renal flow in patients undergoing general anes-
thesia (12). However, no information is available regarding the
effect of adenosine on the renal circulation in patients with
CHF. An understanding of the effects of adenosine may be
important for future development for therapeutic interven-
tions for enhancement of renal function in such patients. The
present study was therefore designed to evaluate the effect of
exogenous adenosine on renal hemodynamic variables in pa-
tients with chronic symptomatic CHF.
Methods
Patients. Nine patients with a history of CHF from left
ventricular (LV) systolic dysfunction who underwent diagnos-
tic cardiac catheterization were included in the study. All
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patients were of male gender, and their age ranged from 30 to
64 (mean 46 6 5 SEM). The etiology of CHF was coronary
artery disease in four patients and unknown in five. LV systolic
dysfunction was diagnosed by either contrast or radionucleide
ventriculography, and mean LV ejection fraction was 26 6 4%.
The group mean hemodynamic values as measured during
cardiac catheterization were heart rate 88 6 7 beats/min, mean
arterial blood pressure 92 6 3 mm Hg, mean right atrial
pressure 9 6 2 mm Hg, mean pulmonary artery pressure 30 6
4 mm Hg, mean pulmonary artery wedge pressure 19 6
3 mm Hg, cardiac index 3.3 6 0.4 liters/min per m2, systemic
vascular resistance 1,480 6 355 dyneszszcm25 and pulmonary
vascular resistance 192 6 68 dyneszszcm25.
Study protocol. All patients signed a consent form ap-
proved by the research committee of the Los Angeles County/
University of Southern California Medical Center. After com-
pletion of diagnostic cardiac catheterization, an 8F angioplasty
multipurpose or Judkins right coronary artery guiding catheter
was placed in the proximal portion of the renal artery, and the
catheter position was confirmed with a small amount of
angiographic contrast medium (Hexibrix, Mallincroft Medi-
cal). A Doppler guide wire (0.018-in. [0.045 cm]) (Flow-wire,
Cardiometrics) was then introduced into the guiding catheter
through a valved sidearm connector and its tip positioned in
the main renal artery. A 3.5F intravascular ultrasound catheter
(Mansfield, Boston Scientific) was then placed in a similar
fashion and was positioned next to the Doppler wire. Images
were obtained with a commercially available intracoronary
ultrasound imaging system (Sono Intravascular, Hewlett-
Packard) at 30 frames/s and recorded on 0.5-in. high quality
super VHS videotape for subsequent off-line analysis. Renal
artery lumen planimetry was later performed from the taped
images, and cross-sectional area was determined with specially
designed software. The spectral Doppler renal blood flow
velocities were recorded, and the velocity–time integral was
measured as the area under the outermost portion of the
spectral velocity envelope. To correct for changes related to
respiration and cardiac cycle, 15 to 30 beats were used for
measurements of both renal artery cross-sectional area and
Doppler velocity–time integral, and average values are re-
ported.
Renal blood flow (in ml/min) was calculated as the product
of the renal artery cross-sectional area and the velocity–time
integral using the following formula: Flow 5 Heart rate per
minute 3 Velocity–time integral 3 Cross-sectional area. Renal
vascular resistance (RVR) was calculated as follows: 80 3
(Mean renal artery blood pressure/RBF).
Renal artery pressures were measured directly with the aid
of the arterial catheter, fluid-filled pressure tubing and stan-
dard transducers. Infusion of adenosine was performed
through the arterial catheter directly into the renal artery.
Adenosine (Fujisawa) was mixed in 5% dextrose in water to
achieve a blood concentration of 1025 mol/liter, assuming an
average RBF of 600 ml/min in patients with CHF (15).
Baseline measurements were performed after 3 min of renal
intraarterial infusion of 5% dextrose in water and included the
measurements of renal artery blood pressures, heart rate,
intravascular ultrasound and Doppler flow velocity. After
baseline hemodynamic measurements, infusion of adenosine
into the renal artery was started, and measurements were
repeated at 2 to 3 min.
Data analysis. A paired Student t test was used to deter-
mine the effect of exogenous adenosine on heart rate, renal
artery blood pressures, renal artery cross-sectional area, Dopp-
ler velocity–time integral and calculated RBF and RVR.
Results are expressed as mean value 6 SE; p # 0.05 was
considered statistically significant.
Results
Administration of adenosine into the renal artery was not
associated with any significant changes in both heart rate (86 6
7 to 85 6 8 beats/min, p 5 NS) and renal artery blood pressure
(92 6 4 to 91 6 4 mm Hg, p 5 NS) (Fig. 1). The Doppler-
measured velocity–time integral (Fig. 2 and 3) was reduced by
59 6 5% from 25 6 5 to 10 6 2 m (p 5 0.001). Calculated RBF
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AMP 5 adenosine monophosphate
CHF 5 congestive heart failure
LV 5 left ventricular
RBF 5 renal blood flow
RVR 5 renal vascular resistance
Figure 1. Effect of intrarenal artery adminis-
tration of adenosine on mean group values of
heart rate and mean renal artery pressure.
BL 5 baseline.
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was markedly reduced in all patients (Fig. 4). The group mean
value for RBF was reduced 61 6 4% from 376 6 36 to 146 6
22 ml/m2 (p 5 0.0002). RVR (Fig. 5) calculated from renal
artery pressure and RBF demonstrated a 171 6 113% increase
from 11,204 6 1,469 to 31,494 6 3,911 dyneszszcm25 (p 5
0.0005). In contrast to these findings, no change was seen in
renal artery cross-sectional area (Fig. 6) on intravascular
ultrasound (0.389 6 0.040 vs. 0.375 6 0.033, p 5 0.3).
Discussion
Adenosine is an ubiquitous nucleoside that is present in the
kidneys (5). Adenosine receptors have been identified in
glomeruli, cortical collecting tubule cells and the renal papilla
and seem to play a regulatory role both in normal renal
physiology as well as in abnormal conditions (4–7,16–21).
Although adenosine is a potent vasodilator in most vascular
beds, its renal circulatory actions are complex. The net circu-
latory effects depend on the balance between the vasoconstric-
tive effect of adenosine A1 receptors and the vasodilatory effect
mediated by adenosine A2 receptors (8). In addition, salt
balance and renin activity have been shown to play a role (9).
RBF is often reduced in patients with CHF and may lead to
impairment of renal function (1,2). Although the effect of
adenosine on renal circulation has been studied in various
animal models and in humans, no information is available
regarding the renal circulatory effects of this substance in
patients with CHF. Our study, which is to our knowledge the
first attempt to evaluate the effect of exogenous adenosine on
the renal circulation in patients with CHF, demonstrates a
marked vasoconstrictive effect of adenosine on the renal
circulation, resulting in a substantial increase in RVR and a
concomitant fall in RBF in all patients.
Although the present study does not provide mechanistic
insight into the renal vascular and hemodynamic effects of
adenosine in patients with CHF, previous studies (18–20)
demonstrating the ability to block responses to exogenous
adenosine in vitro indicate that the vasoconstrictive effect is
receptor mediated. Furthermore, animal studies (8,19,21) us-
ing specific adenosine receptor antagonists have confirmed
that the vasoconstrictor effect of adenosine is due to the
exclusive presence of receptors of the A1 subtype in the kidney.
Activation of these receptors has been reported (18,22) to lead
to an inhibition of adenyl cyclase activity and to decreased
intracellular cyclic adenosine monophosphate (AMP) levels.
At the same time, the observation that adenosine results in
some tissues in stimulation and in others in inhibition of cyclic
AMP production led to the conclusion that these responses
were mediated by different receptor types. Numerous studies
have confirmed the presence of vasodilating adenosine A2
receptor subtype both in preglomerular and postglomerular
Figure 3. Individual and group mean values for Doppler-measured
velocity–time integral (cm) (mean 6 SE). BL 5 baseline. p 5 0.001.
Figure 4. Individual and group mean values for calculated RBF flow
(ml/min per m2) (mean 6 SE). BL 5 baseline. *p 5 0.0002.
Figure 5. Individual and group mean values for calculated renal
vascular resistance (dyneszszcm25) (mean 6 SE). BL 5 baseline. p 5
0.0005.
Figure 2. Doppler flow velocity signal measured in the renal artery at
baseline and during adenosine infusion in one of the study patients.
Velocity time interval (VTI) demonstrated a marked reduction, with
only a small change in renal artery cross-sectional area (CSA).
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vessels. The stimulation of A2 receptors has been shown (18) to
lead to vasodilation secondary to an increase in intracellular
cyclic AMP levels.
Although the administration of exogenous adenosine in the
present study resulted in a substantial reduction of RBF in all
patients, it was not associated with any significant change in the
size of the large renal artery as determined by intravascular
ultrasound. These findings suggest that the vasoconstrictive
action of adenosine in the kidney is due to its effect on small
resistance vessels rather than on large conductance vessels.
This conclusion is supported by animal experiments (18,21)
demonstrating adenosine-mediated vasoconstriction of affer-
ent and efferent glomerular arterioles reflecting the presence
of adenosine A1 receptors on these intrarenal blood vessels.
The present study was designed to evaluate the direct effect
of adenosine on the renal circulation. The drug was infused
into the renal artery to avoid renal changes mediated by
potential systemic effects (14,23,24). Lack of any systemic
effect was evidenced by the stability of heart rate and systemic
blood pressure demonstrated during adenosine infusion. Ed-
lund et al. (14) reported a small increase in heart rate observed
during adenosine infusion into the renal artery in normal
subjects. These investigators postulated an activation of affer-
ent nerves to the central nervous system induced by adenosine
receptors in the kidney. However, this suggestion is not
supported by our results demonstrating a lack of a significant
change in heart rate during intrarenal adenosine infusion.
Study limitations. The present study was designed to eval-
uate the renal circulatory effect of exogenous adenosine at a
dose comparable to that used to achieve an effect in other
vascular beds (25) and at a previously evaluated concentration
in the kidney tissue (26). A dose-related effect of adenosine has
been demonstrated by Inscho et al. (27) who reported vaso-
constriction of afferent arteriolar vessels with a lower concen-
tration and vasodilation at a higher concentration from stim-
ulation of the lower affinity adenosine A2 receptors. It is
therefore unclear whether the results of our study can be
applicable to the effect of endogenous adenosine. However, it
has been suggested (6,28) that under physiologic conditions,
the extracellular free adenosine concentration is low and is
predominantly mediated by A1 receptor activity. This sugges-
tion is further supported by a reported reduction in the
glomerular filtration rate caused by A1 receptor-mediated
afferent arteriolar vasoconstriction found when endogenous
adenosine production is stimulated by pharmacologic maneu-
vers (21,22,29). Although the luminal presentation of exoge-
nous adenosine to the renal vascular cells should be similar to
that of circulating endogenous adenosine, the adventitial pre-
sentation of intrarenally produced adenosine may result in a
different action. However, the use of topically applied adeno-
sine, which approaches the vasculature through the interstitial
compartment and is probably more indicative of the effect of
endogenous adenosine, has also been reported (30) to produce
a renal vasoconstrictive effect similar to that seen in our study.
An additional limitation of the study could be related to the
use of angiotensin-converting enzyme (ACE) inhibitors as part
of CHF therapy. Numerous reports (17,31) have indicated that
angiotensin II may be an important modulator of adenosine-
induced renal hemodynamic effect. Although ACE inhibitors
were discontinued at least 14 h before the initiation of our
study, a residual effect of these drugs could have attenuated the
vasoconstrictive action of adenosine.
Clinical implications. Reduction of RBF is common in
patients with chronic CHF and is an important cause of acute
and chronic renal dysfunction. The results of the present study
demonstrate a significant renal vasoconstrictive effect medi-
ated by stimulation of adenosine receptors. These findings may
indicate a possible role for inhibition of adenosine receptors as
a therapeutic target aiming to increase RBF in patients with
chronic CHF. Such a possibility seems to be supported by
numerous studies (6,32,33) in animals and humans demon-
strating a significant increase in RBF and improvement of the
glomerular filtration rate with the use of adenosine A1 recep-
tor antagonists. An additional benefit of renal adenosine
receptor blockade shown in various animal models and in
normal human subjects has been a significant diuretic and
natriuretic effect (6,28,33–35). Yamagata et al. (34) have also
demonstrated in anesthetized dogs that the diuretic and natri-
uretic effect of adenosine, which was mediated mainly by
inhibition of reabsorption of water and sodium at tubular sites,
was associated with only a minimal kaliuretic effect.
Conclusions. The results of the present study demonstrate
a potent vasoconstrictive effect of adenosine on the renal
circulation in patients with CHF, leading to a marked increase
in RVR and a reduction in RBF. Lack of effect on the luminal
cross sectional area of the large conductance renal arteries
indicates that adenosine exerts its vasoconstrictive effect on the
intrarenal resistance blood vessels. This effect is likely to be
due to stimulation of adenosine A1 subtype receptors in the
kidney. The findings of this study and previous reports on
enhancement of RBF, glomerular filtration rate, urine produc-
tion and sodium excretion with adenosine A1 receptor antag-
onists may suggest a rationale for the investigation of adeno-
sine A1 receptor blockade for enhancement of RBF and
improvement of renal function in patients with chronic CHF.
Figure 6. Individual and group mean values for renal artery cross-
sectional area (cm2) (mean 6 SE) measured by intravascular ultra-
sound. BL 5 baseline.
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